Medical Condition

gram negative bacterial infections

Total Trials

2

Recruiting Now

2

Trial Phases

Phase 2

ClinicalMetric tracks all active clinical trials for gram negative bacterial infections sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Trial Phases

Phase 2

Top Sponsors

Pfizer 1 trial

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 1 trial

NCT05639647 Phase 2

Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Enrollment

48 pts

Location

United States, China...

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Gamaleya Research Institute of...

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology